Reply to E.R. Haspinger et al
Journal
Journal of Clinical Oncology
Journal Volume
32
Journal Issue
8
Pages
863-864
Date Issued
2014
Author(s)
Sequist L.V.
SDGs
Other Subjects
afatinib; anaplastic lymphoma kinase; cisplatin; crizotinib; erlotinib; gefitinib; pemetrexed; afatinib; antineoplastic agent; epidermal growth factor receptor; quinazoline derivative; cancer chemotherapy; cancer patient; cancer research; epidermal growth factor receptor gene; Europe; gastrointestinal stromal tumor; genotype; human; intention to treat analysis; letter; lung adenocarcinoma; lung cancer; melanoma; mutator gene; outcome assessment; patient selection; priority journal; solid tumor; systematic review (topic); United States; validation study; adenocarcinoma; female; genetics; lung tumor; male; note; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Quinazolines; Receptor, Epidermal Growth Factor
Publisher
American Society of Clinical Oncology
Type
letter